Teva- Pharmaceutical Industries Ltd

NYSE: TEVA
$17.65
+$0.22 (+1.3%)
Real Time Data Delayed 15 Min.

TEVA Articles

The top analyst upgrades, downgrades and initiations seen on Friday morning include FireEye, Occidental Petroleum, SeaWorld, Teva Pharmaceutical, Windstream and Zynga.
Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.
24/7 Wall St. has put together a preview of Pfizer, Chesapeake Energy and other major companies reporting their quarterly results this week.
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and they keep getting lower even beyond basic logic.
Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector also hurt most generic drug makers.
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity to buy into the markets and...
The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked...
This week's top value calls from the analysts at Jefferies focus on blue chip companies that are, for the most part, very liquid and offer a degree of safety for investors.
Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive and allow for accelerating growth in the years to come.
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.